Long-term results of Berlin-Frankfurt-Muenster based therapy for childhood and adolescents’ lymphoblastic lymphoma

   Lymphoblastic lymphoma (LBL) is one of predominant childhood non-Hodgkin’s lymphoma (NHL) subtypes and consists 25—30 %.

   The study purpose was to investigate outcomes in children and adolescents with LBL treated with protocol NHL-BFM-90 and 95 in the Moscow region.

   58 primary patients (m–40, f–18) with T- and B-LBL were enrolled from 05. 1991 to 08. 2008 (aged 1.5–21.6 years; median 11.0 years). Fifty-two (90 %) patients were treated with ALL-like therapy protocol NHL-BFM-90 or 95 for non-B-NHL and 6 (10 %) — NHL-BFM-90 for B-NHL. The complete response (CR) rate was 94 and 83 %, respectively. 5-years event-free survival (5y-EFS) was 0.80 ± 0.06 (median of observation 4.1 years) and 0.67 ± 0.19 (5.1 years), respectively (p > 0.05). 5-years overall survival (5y-OS) was 0.85 ± 0.05 and 0.80 ± 0.06 respectively (p > 0.05). The situation without mediastinal involvement was a factor unfavorable prognosis for T-LBL: 5y-EFS — 0.56 ± 0.17 vs. 0.90 ± 0.05 (p = 0.036). Thus the NHL-BFM-90 and 95 for non-B-NHL protocols are effective therapeutic regimes for pediatric LBL and obtained long-term results are comparable with international data.

1. Izarzugaza M. I., Steliarova-Foucher E., Martos M. C., Zivkovic S. Non-Hodgkin's lymphoma incidence and survival in European children and adolescents (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006; 42 (13): 2050–63.

2. Hoelzer D., Gokbuget N., Digel W. et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002; 99 (12): 4379–85.

3. Neth O., Seidemann K., Jansen P. et al. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM-86 and 90. Med Pediatr Oncol 2000; 35 (1): 20–7.

4. Reiter A., Schrappe M., Ludwig W. D. et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95 (2): 416–21.

5. Burkhardt B., Woessmann W., Zimmermann M. et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006; 24 (3): 491–9.

6. Millot F., Suciu S., Philippe N. et al. Value of high-dose cytarabine during interval therapy of a BFM-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the EORTC 58881 randomized phase III trial. J Clin Oncol 2001; 19 (7): 1935–42.

7. Semochkin S. V., Kulikova S. S., Bobkova M. M. et al. Results of ALL-MB 91/2002 protocol in Adolescents and Young Adults with Lymphoblastic Lymphoma: Single Institution Experience in Russia. Hematology Meeting Reports 2009; 3 (5): 39.

8. Borowitz M. J., Chan J. K. C. Precursor Lymphoid Neoplasms [book auth.]. Campo E., Harris N. L. et al. (eds.) Swerdlow S. H. WHO classificatin of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2008; p.167–78.

9. Murphy S. B. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980; 7 (3): 332–9.

10. Reiter A., Schrappe M., Tiemann M. et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM-90. Blood 1999; 94 (10): 3294–306.

11. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53: 457–81.

12. Voakes J. B., Jones S. E., McKelvey E. M. The chemotherapy of lymphoblastic lymphoma. Blood 1981; 57: 186–8.

13. Mora J., Filippa D. A., Qin J., Wollner N. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer 2003; 98 (6): 1283–91.

14. Abromowitch M., Termuhlen A., Lynch J. et al. High-dose methotrexate and early intensification of therapy do not improve 3 years EFS in children and adolescents with disseminated lymphoblastic lymphoma. Results of the randomized arms of COG A5971. Hematology Meeting Reports 2009; 3 (5): 33–4.

15. Cox J. D., Ha C. S., Lee H. K. et al. Uncertainties in contemporary treatment of aggressive lymphomas. Rays 2003; 28 (3): 289–92.

16. Petrie H. T. Cell migration and the control of post-natal T-cell lymphopoiesis in the thymus. Nat Rev Immunol 2003; 3 (11): 859–66.

17. Macintyre E. Biology of T-cell lymphoblastic lymphoma. Hematology Meeting Reports 2009; 3 (5): 32.

18. Baleydier F., Decouvelaere A. V., Bergeron J. et al. T-cell receptor genotyping and HOXA/TLX1 expression define three T-lymphoblastic lymphoma subsets which might affect clinical outcome. Clin Cancer Res 2008; 14 (3): 692–700.